(Q37744505)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20448659%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

review article

1 reference

title

Functional imaging of renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20448659%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20448659%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Andrew M Scott

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20448659%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Ian D Davis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20448659%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Damien M Bolton

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20448659%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

English

0 references

publication date

1 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20448659%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

published in

Nature Reviews Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20448659%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20448659%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20448659%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

258-266

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20448659%20AND%20SRC:MED&resulttype=core&format=json

A combined PET/CT scanner: the path to true image fusion

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Rising incidence of renal cell cancer in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Epidemiology and risk factors for kidney cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Targeted therapies in the treatment of renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Seven years after laparoscopic radical nephrectomy: oncologic and renal functional outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Current practice patterns in the use of ablation technology for the management of small renal masses at academic centers in the United States.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Current status of positron emission tomography in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Positron emission tomography in urological malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Recent developments in urologic oncology: positron emission tomography molecular imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Multidetector computed tomography vs magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: a study and review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Preoperative imaging in renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

PET/CT: will it change the way that we use CT in cancer imaging?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Diagnosis of Occult Bone Metastases: Positron Emission Tomography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Detection of tumour thrombus by 18F-FDG-PET/CT imaging.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

PET scans for decision-making in metastatic renal cell carcinoma: a single-institution evaluation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Will targeted therapy hold its promise? An evidence-based review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

11C-Acetate PET imaging for renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Monitoring response to treatment in patients utilizing PET.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Fluorine-18 Fluorothymidine: A New Positron Emission Radioisotope for Renal Tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Expression of CD24 in clear cell renal cell carcinoma and its prognostic significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Lymphangiogenesis and angiogenesis in conventional renal cell carcinoma: association with vascular endothelial growth factors A to D immunohistochemistry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Metastatic renal cell carcinoma: recent advances in the targeted therapy era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Cytoreductive Partial Nephrectomy Does Not Undermine Cancer Control in Metastatic Renal Cell Carcinoma: A Population-Based Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Antibodies and antimatter: the resurgence of immuno-PET.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

G250: a carbonic anhydrase IX monoclonal antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Trials and tribulations: oncological antibody imaging comes to the fore

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Differentiating Solitary Pulmonary Metastases in Patients with Renal Cell Carcinomas by <sup>18</sup>F-Fluoro-2-Deoxyglucose Positron Emission Tomography – A Preliminary Report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

FDG PET characterization of renal masses: preliminary experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Positron emission tomography in urological oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.40

In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations

31 March 2020

1 reference

12 December 2020

[Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results]

1 reference

12 December 2020

Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice

1 reference

12 December 2020

Clinical experience with the first combined positron emission tomography/computed tomography scanner in Australia.

1 reference

12 December 2020

18F-fluorocholine: a new oncologic PET tracer

1 reference

12 December 2020

Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.

1 reference

12 December 2020

Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data

1 reference

12 December 2020

[Positron emission tomography in diagnosis of renal cell carcinoma]

1 reference

12 December 2020

Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera.

1 reference

12 December 2020

Current surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunologic approach to renal-cell carcinoma.

1 reference

12 December 2020

Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma

1 reference

12 December 2020